title: Tolerability of long term therapy with enalapril maleate in patients resistant to other therapies and intolerant to captopril.
abstract: Patients with severe hypertension and/or congestive heart failure (n = 281) who were unresponsive to other therapies and intolerant to captopril received enalapril treatment (mean dose 19.5 mg/day) under study conditions as part of a Compassionate Use Program. Many of these patients had serious concurrent disorders known to predispose them to a greater risk of adverse experiences and death. The mean duration of enalapril treatment was 29 weeks, with a range of 1 day to approximately 3.5 years. Enalapril was generally well tolerated, and the estimated long term probability of patients terminating enalapril therapy because of adverse effects was low. 20 patients had discontinued captopril treatment because of low white blood cell counts; during subsequent enalapril treatment these reactions resolved in 14 patients, persisted in 2 patients, and could not be evaluated in 4 patients. Captopril-related proteinuria improved or resolved in 9 and persisted in 2 of 15 patients, taste disturbances resolved in 35 and persisted in 2 of 38 patients; and rash resolved in all but 7 of 178 patients during enalapril treatment. 18 patients (6%) discontinued enalapril treatment because of lack of efficacy; 6 of these 18 patients died due to a progression of heart failure, and another 11 patients died for other reasons. The deaths were considered unrelated to therapy with enalapril. Adverse reactions were the reason for discontinuation of enalapril treatment in 53 patients (19%). The most common adverse experiences that resulted in discontinuation of enalapril were: impairment of renal function (5%), hypotension (2%) and rash (2%). No neutropenia, proteinuria, or new taste disturbances were recorded as reasons for discontinuation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cardio Renal Clinical Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania.
authors.forename: E J
authors.initials: EJ
authors.lastname: Rucinska
authors.forename: R
authors.initials: R
authors.lastname: Small
authors.forename: W S
authors.initials: WS
authors.lastname: Mulcahy
authors.forename: D L
authors.initials: DL
authors.lastname: Snyder
authors.forename: P V
authors.initials: PV
authors.lastname: Rodel
authors.forename: J E
authors.initials: JE
authors.lastname: Rush
authors.forename: R D
authors.initials: RD
authors.lastname: Smith
authors.forename: J F
authors.initials: JF
authors.lastname: Walker
authors.forename: J D
authors.initials: JD
authors.lastname: Irvin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002216:Captopril / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D004347:Drug Interactions; D004656:Enalapril / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000139:chemically induced; D012307:Risk Factors; D013651:Taste Disorders / Q000139:chemically induced
chemical_list: D004656:Enalapril; D002216:Captopril